Cypress Bioscience, Inc.
Records under this name other than the patents Cypress Bioscience, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Cypress Bioscience, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,994,220 | Milnacipran for the Long-Term Treatment of Fibromyalgia Syndrome Formerly held In force · High confidence | In force | High confidence | |
| US 7,563,590 | Methods of Quantifying Methotrexate Metabolites Term ended Term ended Jan 23, 2025 · High confidence | Term ended | Term ended Jan 23, 2025 | High confidence |
| US 6,602,911 | Methods of treating fibromyalgia Formerly held Term ended Term ended Jan 14, 2023 · From the USPTO record | Term ended | Term ended Jan 14, 2023 | From the USPTO record |
| US 7,820,643 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain Formerly held Term ended Term ended May 12, 2022 · From the USPTO record | Term ended | Term ended May 12, 2022 | From the USPTO record |
| US 6,992,110 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain Formerly held Term ended Term ended Nov 17, 2021 · From the USPTO record | Term ended | Term ended Nov 17, 2021 | From the USPTO record |
| US 6,635,675 | Method of treating chronic fatigue syndrome Formerly held Term ended Term ended Nov 12, 2021 · From the USPTO record | Term ended | Term ended Nov 12, 2021 | From the USPTO record |
| US 7,888,342 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain Formerly held Term ended Term ended Nov 5, 2021 · From the USPTO record | Term ended | Term ended Nov 5, 2021 | From the USPTO record |
| US 7,915,246 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain Term ended Ended no later than Nov 5, 2021 · From the USPTO record | Term ended | Ended no later than Nov 5, 2021 | From the USPTO record |
| US 9,023,793 | Intranasal carbetocin formulations and methods for the treatment of autism Formerly held Lapsed on the fee record Ended May 5, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 5, 2019 | From the USPTO record |
| US 6,894,026 | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders Formerly held Lapsed on the fee record Ended May 17, 2013 · From the USPTO record | Lapsed on the fee record | Ended May 17, 2013 | From the USPTO record |